. Author manuscript; available in PMC: 2021 Aug 10.

Published in final edited form as: Int Arch Allergy Immunol. 2020 Aug 10;181(11):879–887. doi: 10.1159/000509600

Table 4.

Plasma P-selectin concentration at baseline, post-intramuscular triamcinolone acetonide (TA) administration, during exacerbation and recovery, and 36 months post-baseline

	Visit
Variable	Baseline	Post-TA	Acute exacerbation	Recovery post-exacerbation	36 months post-baseline
P-selectin, ng/ml	23.2 (15.6, 34.4)	22.4 (16.9, 29.4)	26.4 (19.8, 33.0)	30.0 (21.3, 34.8)^*^††	23.2 (18.2, 29.4)
-“-, % of baseline	100	92 (66, 139)	117 (79, 152)^*	127 (84, 174)^*^†^#^§	89 (75, 122)

Data are presented as median (25^th, 75^th percentiles), n = 70, 70, 26, 26, and 60 for the different visits, respectively.

p ≤ 0.05 versus the 36 months visit;

^††

p ≤ 0.01 versus the acute exacerbation visit.

^†

p ≤ 0.05 versus the acute exacerbation visit;

p ≤ 0.05 versus the baseline visit;

^§

p ≤ 0.05 versus the post-TA visit.